DPPA2 activators are a specialized group of chemical agents formulated to enhance the biological activity of the Developmental Pluripotency Associated 2 (DPPA2) protein. DPPA2 is a member of the family of developmental pluripotency-associated proteins and plays an integral role in the regulation of gene expression, particularly those genes that are essential for maintaining the pluripotent state of stem cells. Activators of DPPA2 function by promoting its ability to bind to DNA and modulate transcriptional processes. The specific molecular interactions facilitated by these activators can lead to a conformational change in DPPA2, increasing its affinity for DNA or its ability to recruit other factors necessary for transcriptional activation. These activators often target the protein's DNA-binding domain or other regions crucial for its interaction with chromatin or transcriptional co-activators.
The design of DPPA2 activators is a sophisticated process that hinges on a detailed understanding of the protein's structure and the conformational dynamics that underpin its function in gene expression. Typically, the development of such activators involves the identification of key binding sites on the DPPA2 protein that are amenable to small molecule interaction. These sites may be involved in the protein's interaction with DNA or with other proteins that are part of the transcriptional apparatus. Activators may be designed to mimic or stabilize interactions between DPPA2 and its physiological partners, or they may stabilize the active form of DPPA2.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
A 83-01 | 909910-43-6 | sc-203791 sc-203791A | 10 mg 50 mg | $202.00 $811.00 | 16 | |
A selective inhibitor of TGF-β type I receptor ALK5 kinase, which can upregulate pluripotency factors potentially including DPPA2 by inhibiting differentiation signals. | ||||||
Y-27632, free base | 146986-50-7 | sc-3536 sc-3536A | 5 mg 50 mg | $186.00 $707.00 | 88 | |
A ROCK inhibitor that enhances the survival and cloning efficiency of pluripotent stem cells, which can maintain DPPA2 expression by supporting an undifferentiated cell state. | ||||||
Forskolin | 66575-29-9 | sc-3562 sc-3562A sc-3562B sc-3562C sc-3562D | 5 mg 50 mg 1 g 2 g 5 g | $78.00 $153.00 $740.00 $1413.00 $2091.00 | 73 | |
An activator of adenylate cyclase, increasing cAMP levels, which has been used to enhance the efficiency of iPSC generation, potentially impacting DPPA2 expression. | ||||||
Tranylcypromine | 13492-01-8 | sc-200572 sc-200572A | 1 g 5 g | $175.00 $599.00 | 5 | |
A non-selective inhibitor of lysine-specific demethylase 1 (LSD1), which can lead to increased histone methylation and potentially upregulate genes associated with pluripotency, including DPPA2. | ||||||
Valproic Acid | 99-66-1 | sc-213144 | 10 g | $87.00 | 9 | |
A histone deacetylase inhibitor that can improve reprogramming efficiency of iPSCs, potentially influencing DPPA2 expression by changing the epigenetic state of pluripotency genes. | ||||||
Parthenolide | 20554-84-1 | sc-3523 sc-3523A | 50 mg 250 mg | $81.00 $306.00 | 32 | |
An NF-kB inhibitor that also shows potential in enhancing stem cell pluripotency, which could lead to the stabilization of DPPA2 expression. | ||||||
SQ 22536 | 17318-31-9 | sc-201572 sc-201572A | 5 mg 25 mg | $95.00 $363.00 | 13 | |
An adenylate cyclase inhibitor that can alter cAMP levels, potentially affecting cellular processes that maintain pluripotency and indirectly influencing DPPA2 expression. | ||||||